Cardiovascular Drugs Dealers in Borivali, Mumbai

• Form: Tablets / Liquid / Capsules / Powder
• Packaging Type: Plastic Bottle
• Usage: Clinical, hospital etc.
• CATEGORY: Thrombolytic
• Dosage: 5mg
• Grade Standard: Medicine Grade
• Storage: Cool and Dry Place
• Storage: Cool and Dry Place

Streptokinase  Injection 2.5 / 5 / 7.5 / 15 Lac IU is used in Acute Evolving Transmural Myocardial Infarction:  Streptokinase, is indicated for use in the management of acute myocardial infarction (AMI) in adults, for the iysis of intracoronary thrombi, the improvement of ventricular function, and the reduction of mortality associated with AMI, when administered by either the intravenous or the intracoronary route, as well as for the reduction of infarct size and congestive heart failure associated with AMI when administered by the intravenous route. Pulmonary Embolism: Streptokinase, is indicated for the lysis of objectively diagnosed (angiography or lung scan) pulmonary emboli, involving obstruction of blood flow to a lobe or multiple segments, with or without unstable hemodynamics. Deep Vein Thrombosis: Streptokinase, is indicated for the lysis of objectively diagnosed (preferably ascending venography), acute, extensive thrombi of the deep veins such as those involving the popliteal and more proximal vessels. Arterial Thrombosis or Embolism: Streptokinase, is indicated for the lysis of acute arterial thrombi and emboli. Streptokinase is not indicated for arterial emboli originating from the left side of the heart due to the risk of new embolic phenomena such as cerebral embolism. Occlusion of Arteriovenous Cannulae: Streptokinase, is indicated as an alternative to surgical revision for clearing totally or partially occluded arteriovenous cannulae when acceptable flow cannot be achieved. There are many generic manufacturers in India who manufacture Streptokinase  Injection 2.5 / 5 / 7.5 / 15 Lac IU including Zydus Cadila Healthcare ,Biocon(India)Ltd and Piramal Healthcare  etc. 3s corporation is Supplier,Exporter ,Wholesaler  for Streptokinase  Injection 2.5 / 5 / 7.5 / 15 Lac IU in India.     ADDITIONAL INFORMATION Administer Streptokinase as soon as possible after onset of symptoms. The greatest benefit in mortality reduction was observed when Streptokinase was administered within four hours, but statistically significant benefit has been reported up to 24 hours.   SIDE EFFECTS Bleeding:   The reported incidence of bleeding (major or minor) has varied widely depending on the indication, dose, route and duration of administration, and concomitant therapy. Minor bleeding can be anticipated mainly at invaded or disturbed sites. If such bleeding occurs, local measures should be taken to control the bleeding. Severe internal bleeding involving gastrointestinal (including hepatic bleeding), genitourinary, retroperitoneal, or intracerebral sites has occurred and has resulted in fatalities. In the treatment of acute myocardial infarction with intravenous Streptokinase, the GISSI and ISIS-2 studies reported a rate of major bleeding (requiring transfusion) of 0.3-0.5%. However, rates as high as 16% have been reported in studies which required administration of anticoagulants and invasive procedures. Allergic Reactions:  Fever and shivering, occurring in 1-4% of patients(1,2) , are the most commonly reported allergic reactions with intravenous use of Streptase, Streptokinase, in acute myocardial infarction. Anaphylactic and anaphylactoid reactions ranging in severity from minor breathing difficulty to bronchospasm, periorbital swelling or angioneurotic edema have been observed rarely. Other milder allergic effects such as urticaria, itching, flushing, nausea, headache and musculoskeletal pain have also been observed, as have delayed hypersensitivity reactions such as vasculitis and interstitial nephritis.  Respiratory:   There have been reports of respiratory depression in patients receiving Streptokinase. In some cases, it was not possible to determine whether the respiratory depression was associated with Streptokinase or was a symptom of the underlying process. If respiratory depression is associated with Streptokinase, the occurrence is believed to be rare. Other Adverse Reactions:   Transient elevations of serum transaminases have been observed. The source of these enzyme rises and their clinical significance is not fully understood.

Benzoyl Chloride, Allyl alcohol, aluminum chloride, Acetazolamide